Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200mg twice daily to nevirapine extended release 400mg once daily (TRANxITION).

Authors

Keikawus N. Arasteh, Vivantes Auguste-Viktoria Hospital, Berlin, Germany
Douglas J. Ward, George Washington University
Andreas Plettenberg, Asklepios Hospital St. Georg, Hamburg, Germany
Jean M. Livrozet, Edouard Herriot Hospital, Lyon, France
Chloë M. Orkin, Barts and the London NHS Trust, London, United Kingdom
Christiane Cordes, PraxisCityOst, Berlin Germany
J. Guo, Boehringer Ingelheim Pharmaceuticals, Inc.
Elaine Wang, Boehringer Ingelheim Pharmaceuticals, Inc.
ChanLoi Yong, Boehringer Ingelheim Pharmaceuticals, Inc.
Patrick A. Robinson, Boehringer Ingelheim Pharmaceuticals, Inc.
Anne M. Quinson, Boehringer Ingelheim Pharmaceuticals, Inc.

Document Type

Journal Article

Publication Date

4-2012

Journal

HIV Medicine

Volume

Volume 13, Issue 4

Inclusive Pages

236-244

Keywords

Anti-HIV Agents--administration & dosage; Drug Substitution; HIV Infections--drug therapy; HIV-1; Nevirapine--administration & dosage

APA Citation

Arasteh, K., Ward, D., Plettenberg, A., Livrozet, J. M., Orkin, C., Cordes, C., . . . Quinson, A. (2012). Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200mg twice daily to nevirapine extended release 400mg once daily (TRANxITION). HIV Medicine, 13(4), 236-244.

Peer Reviewed

1